

Juan Aguilar-Company

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103451/publications.pdf>

Version: 2024-02-01

29
papers

687
citations

686830

13
h-index

610482

24
g-index

30
all docs

30
docs citations

30
times ranked

1172
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474. | 7.7 | 151 |
| 2 | Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680. | 5.1 | 73 |
| 3 | Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841. | 1.7 | 58 |
| 4 | Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114. | 3.4 | 50 |
| 5 | Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875. | 5.1 | 50 |
| 6 | Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983386. | 1.4 | 39 |
| 7 | Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202. | 1.3 | 37 |
| 8 | Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277. | | 30 |
| 9 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) Tj ETQq1 1 0z784314 rgBT /Over | | 28 |
| 10 | Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4398-4400. | 1.4 | 21 |
| 11 | Risk of infection associated with targeted therapies for solid organ and hematological malignancies. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612198954. | 1.1 | 20 |
| 12 | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74. | 1.3 | 19 |
| 13 | The changing epidemiology of spinal tuberculosis: the influence of international immigration in Catalonia, 1993-2014. <i>Epidemiology and Infection</i> , 2017, 145, 2152-2160. | 1.0 | 15 |
| 14 | Native vertebral osteomyelitis in aged patients: distinctive features. An observational cohort study. <i>Infection</i> , 2018, 46, 679-686. | 2.3 | 14 |
| 15 | COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987. | 3.0 | 14 |
| 16 | Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study. <i>Mycoses</i> , 2019, 62, 765-772. | 1.8 | 12 |
| 17 | Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16. | 1.3 | 11 |
| 18 | Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH) Tj ETQq0 0 0 rgBT /Overlaid 10 Tf 50 | | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Molecular Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia by Use of Oral Wash Samples in Immunocompromised Patients: Usefulness and Importance of the DNA Target. <i>Journal of Clinical Microbiology</i> , 2019, 57, . | 1.8 | 9 |
| 20 | Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos. <i>Medicina Clínica</i> , 2020, 154, 101-107. | 0.3 | 8 |
| 21 | Prognosis of <i>Clostridium difficile</i> infection in adult oncohaematological patients: experience from a large prospective observational study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2075-2082. | 1.3 | 6 |
| 22 | COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534. | 1.4 | 5 |
| 23 | Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422. | 1.4 | 4 |
| 24 | Risk of infection associated with new therapies for lymphoproliferative syndromes. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 101-107. | 0.1 | 3 |
| 25 | Necrotizing pneumonia caused by community-acquired methicillin-resistant <i>Staphylococcus aureus</i> . <i>Medicina Clínica (English Edition)</i> , 2016, 146, e1-e2. | 0.1 | 1 |
| 26 | <i>Pneumocystis jirovecii</i> genetic diversity in a Spanish tertiary hospital. <i>Medical Mycology</i> , 2021, 60, . | 0.3 | 1 |
| 27 | Reply to "Activity of Fosfomicin on Clinical Isolates of <i>Campylobacter jejuni</i> and <i>Campylobacter coli</i> of Enteric Origin". <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 0 |
| 28 | Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 257-270. | 1.9 | 0 |
| 29 | Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23103-e23103. | 0.8 | 0 |